Dechra Pharmaceuticals PLC
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DPHAY research report →
About the company
Dechra Pharmaceuticals PLC (DPHAY) is dedicated to the development, manufacturing, regulatory approval, marketing, and sale of veterinary medications and related goods specifically for animal health professionals. The company's operations are structured into three key divisions: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceutical Research and Development. Its extensive product portfolio addresses various animal species: For companion animals like dogs and cats, Dechra offers treatments covering endocrine disorders, dermatological conditions, pain relief, anesthesia, cardiovascular health, and critical care.
- CEO
- Ian D. Page
- IPO
- 2018
- Employees
- 2,457
- HQ
- Northwich, GB
Price Chart
- Market Cap
- $5.58B
- P/E
- -161.08
- P/S
- 5.78
- P/B
- 5.81
- EV/EBITDA
- 55.75
- Div Yield
- 0.32%
- Gross Margin
- 55.98%
- Op Margin
- 0.83%
- Net Margin
- -3.66%
- ROE
- -3.92%
- ROIC
- 0.35%
- Revenue
- $761.50M · 11.69%
- Net Income
- $-27,900,000 · -147.94%
- EPS
- $-0.24 · -144.44%
- Op Income
- $6.30M
- FCF YoY
- -26.49%
- 52W High
- $98.00
- 52W Low
- $61.61
- 50D MA
- $94.61
- 200D MA
- $93.00
- Beta
- 0.75
- Avg Volume
- 3
Get TickerSpark's AI analysis on DPHAY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our DPHAY coverage
Recent articles, reports, and earnings notes.
No research on DPHAY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DPHAY report →Similar companies
Peers in the same neighborhood.